TransCode Publishes Novel Tumor Immunotherapy Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy RNAZ?
Source: PRnewswire
- Innovative Immunotherapy: TransCode Therapeutics' published research introduces a novel tumor-selective immunotherapy that activates innate immune signaling within cancer cells, significantly enhancing non-invasive imaging capabilities for drug delivery, potentially transforming cancer treatment paradigms.
- Collaborative Research Findings: Conducted in collaboration with Dr. Anna Moore from Michigan State University, the study utilizes overexpressed oncogenic microRNAs as intracellular assembly templates, successfully addressing challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.
- Clinical Trial Progress: TransCode's TTX delivery platform is currently under evaluation in clinical trials, underscoring the translational feasibility of this immunotherapy approach, which may provide new treatment options for patients with high-risk and advanced cancers.
- Market Potential: TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, highlighting its unique market positioning and potential commercial value in the tumor immunotherapy landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNAZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNAZ
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics
- Exclusive License Agreement: TransCode Therapeutics has signed an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, acquiring rights to develop three drug candidates, UIO-524, UIO-525, and UIO-526, marking a strategic expansion in the field of immuno-oncology.
- Equity Payment Structure: Under the agreement, Unleash will receive 1,136,364 shares of a new series of non-voting convertible preferred stock, equivalent to 6.8% of TransCode's common stock upon conversion, enhancing Unleash's shareholder position while providing TransCode with funding to advance its R&D efforts.
- Market Opportunity: UIO-524, as a next-generation biology-driven oncolytic immunotherapy, aims to address muscle-invasive bladder cancer, a high unmet medical need, potentially opening up a multi-billion-dollar market opportunity for TransCode and strengthening its competitive position in cancer treatment.
- Clinical Trial Progress: TransCode's lead candidate, TTX-MC138, is advancing into a Phase 2a clinical trial, and the introduction of UIO-524 will further enrich its oncology pipeline, enhancing the company's market positioning and therapeutic capabilities in more aggressive disease settings.
See More
TransCode Publishes Novel Tumor Immunotherapy Research
- Innovative Immunotherapy: TransCode Therapeutics' published research introduces a novel tumor-selective immunotherapy that activates innate immune signaling within cancer cells, significantly enhancing non-invasive imaging capabilities for drug delivery, potentially transforming cancer treatment paradigms.
- Collaborative Research Findings: Conducted in collaboration with Dr. Anna Moore from Michigan State University, the study utilizes overexpressed oncogenic microRNAs as intracellular assembly templates, successfully addressing challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.
- Clinical Trial Progress: TransCode's TTX delivery platform is currently under evaluation in clinical trials, underscoring the translational feasibility of this immunotherapy approach, which may provide new treatment options for patients with high-risk and advanced cancers.
- Market Potential: TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, highlighting its unique market positioning and potential commercial value in the tumor immunotherapy landscape.
See More
TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment
- Research Publication: TransCode Therapeutics, in collaboration with Michigan State University, published preclinical research on TTX-MC138 for glioblastoma treatment, demonstrating significant survival improvements, marking a crucial advancement in addressing treatment-resistant cancers.
- Efficacy Validation: The study showed that TTX-MC138 effectively delivered to human glioblastoma in murine models, inducing a five-fold increase in apoptotic activity, further validating its potential to overcome drug delivery barriers.
- Clinical Trial Progress: TTX-MC138 has completed IND studies and toxicity testing, showing good safety in Phase I trials for non-CNS cancers, with a Phase II trial anticipated to begin in the first half of 2026, advancing its clinical application.
- Strategic Implications: This research not only provides robust biological support for TransCode's RNA therapeutic platform but also showcases its broad potential in treating metastatic tumors, potentially transforming the treatment landscape for glioblastoma.
See More
TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models
- Survival Extension: TTX-MC138 successfully delivered via intravenous injection in glioblastoma mouse models significantly extends survival, indicating its potential in treating this highly aggressive cancer.
- Target Mechanism Validation: The study demonstrates that TTX-MC138 effectively suppresses miR-10b, resulting in a five-fold increase in apoptotic activity in tumors, thereby enhancing therapeutic efficacy and supporting its clinical development.
- Preclinical Research Findings: Conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, this study lays the groundwork for the clinical application of TTX-MC138, which is expected to drive future clinical trials.
- Future Clinical Trial Plans: Currently undergoing Phase 1 clinical trials, TTX-MC138 is anticipated to enter Phase 2 trials in the first half of 2026, further validating its potential application in metastatic diseases.
See More
TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience
- Leadership Enhancement: TransCode Therapeutics appoints Jack E. Stover to its Board, bringing over 30 years of leadership experience in the life sciences sector, which is expected to drive the company's strategic development in RNA and immuno-oncology.
- Audit Committee Adjustment: Stover will join the Audit and Nominating Committees, succeeding Dr. Magda Marquet, thereby optimizing the company's governance structure and enhancing financial transparency and compliance.
- Rich Industry Experience: Having served as CEO and director for multiple biopharmaceutical companies, Stover has successfully led various financings and mergers, which is anticipated to provide crucial support for TransCode's capital formation and market expansion.
- Future Development Outlook: Stover expressed eagerness to help advance the mission of a cancer-free future, indicating alignment with the company's vision, which may enhance investor confidence and attract greater attention.
See More
TransCode Appoints Jack E. Stover to Board, Enhancing Oncology Expertise
- Board Appointment: TransCode Therapeutics has appointed Jack E. Stover to its Board of Directors, bringing over 30 years of leadership experience in the life sciences sector, particularly in drug development and capital formation, which is expected to significantly bolster the company's advancements in RNA and immuno-oncology.
- Audit Committee Changes: Stover will join the Audit and Nominating Committees, succeeding Dr. Magda Marquet, thereby enhancing the board's financial and strategic capabilities, which will improve the company's compliance and transparency in a complex regulatory environment.
- Industry Leadership Experience: Stover has served as CEO for multiple biotech firms, including Interpace Biosciences and Antares Pharma, where his successful integration efforts led to a sale for over $900 million, showcasing his exceptional ability to drive company growth.
- Future Development Vision: Stover expressed enthusiasm for helping TransCode achieve its mission of a cancer-free future, indicating the company's long-term commitment and strategic vision in cancer treatment, which may attract increased investor interest in its R&D potential.
See More
TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics
- Exclusive License Agreement: TransCode Therapeutics has signed an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, acquiring rights to develop three drug candidates, UIO-524, UIO-525, and UIO-526, marking a strategic expansion in the field of immuno-oncology.
- Equity Payment Structure: Under the agreement, Unleash will receive 1,136,364 shares of a new series of non-voting convertible preferred stock, equivalent to 6.8% of TransCode's common stock upon conversion, enhancing Unleash's shareholder position while providing TransCode with funding to advance its R&D efforts.
- Market Opportunity: UIO-524, as a next-generation biology-driven oncolytic immunotherapy, aims to address muscle-invasive bladder cancer, a high unmet medical need, potentially opening up a multi-billion-dollar market opportunity for TransCode and strengthening its competitive position in cancer treatment.
- Clinical Trial Progress: TransCode's lead candidate, TTX-MC138, is advancing into a Phase 2a clinical trial, and the introduction of UIO-524 will further enrich its oncology pipeline, enhancing the company's market positioning and therapeutic capabilities in more aggressive disease settings.
See More
TransCode Publishes Novel Tumor Immunotherapy Research
- Innovative Immunotherapy: TransCode Therapeutics' published research introduces a novel tumor-selective immunotherapy that activates innate immune signaling within cancer cells, significantly enhancing non-invasive imaging capabilities for drug delivery, potentially transforming cancer treatment paradigms.
- Collaborative Research Findings: Conducted in collaboration with Dr. Anna Moore from Michigan State University, the study utilizes overexpressed oncogenic microRNAs as intracellular assembly templates, successfully addressing challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.
- Clinical Trial Progress: TransCode's TTX delivery platform is currently under evaluation in clinical trials, underscoring the translational feasibility of this immunotherapy approach, which may provide new treatment options for patients with high-risk and advanced cancers.
- Market Potential: TransCode's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, highlighting its unique market positioning and potential commercial value in the tumor immunotherapy landscape.
See More
TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment
- Research Publication: TransCode Therapeutics, in collaboration with Michigan State University, published preclinical research on TTX-MC138 for glioblastoma treatment, demonstrating significant survival improvements, marking a crucial advancement in addressing treatment-resistant cancers.
- Efficacy Validation: The study showed that TTX-MC138 effectively delivered to human glioblastoma in murine models, inducing a five-fold increase in apoptotic activity, further validating its potential to overcome drug delivery barriers.
- Clinical Trial Progress: TTX-MC138 has completed IND studies and toxicity testing, showing good safety in Phase I trials for non-CNS cancers, with a Phase II trial anticipated to begin in the first half of 2026, advancing its clinical application.
- Strategic Implications: This research not only provides robust biological support for TransCode's RNA therapeutic platform but also showcases its broad potential in treating metastatic tumors, potentially transforming the treatment landscape for glioblastoma.
See More
TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models
- Survival Extension: TTX-MC138 successfully delivered via intravenous injection in glioblastoma mouse models significantly extends survival, indicating its potential in treating this highly aggressive cancer.
- Target Mechanism Validation: The study demonstrates that TTX-MC138 effectively suppresses miR-10b, resulting in a five-fold increase in apoptotic activity in tumors, thereby enhancing therapeutic efficacy and supporting its clinical development.
- Preclinical Research Findings: Conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, this study lays the groundwork for the clinical application of TTX-MC138, which is expected to drive future clinical trials.
- Future Clinical Trial Plans: Currently undergoing Phase 1 clinical trials, TTX-MC138 is anticipated to enter Phase 2 trials in the first half of 2026, further validating its potential application in metastatic diseases.
See More
TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience
- Leadership Enhancement: TransCode Therapeutics appoints Jack E. Stover to its Board, bringing over 30 years of leadership experience in the life sciences sector, which is expected to drive the company's strategic development in RNA and immuno-oncology.
- Audit Committee Adjustment: Stover will join the Audit and Nominating Committees, succeeding Dr. Magda Marquet, thereby optimizing the company's governance structure and enhancing financial transparency and compliance.
- Rich Industry Experience: Having served as CEO and director for multiple biopharmaceutical companies, Stover has successfully led various financings and mergers, which is anticipated to provide crucial support for TransCode's capital formation and market expansion.
- Future Development Outlook: Stover expressed eagerness to help advance the mission of a cancer-free future, indicating alignment with the company's vision, which may enhance investor confidence and attract greater attention.
See More
TransCode Appoints Jack E. Stover to Board, Enhancing Oncology Expertise
- Board Appointment: TransCode Therapeutics has appointed Jack E. Stover to its Board of Directors, bringing over 30 years of leadership experience in the life sciences sector, particularly in drug development and capital formation, which is expected to significantly bolster the company's advancements in RNA and immuno-oncology.
- Audit Committee Changes: Stover will join the Audit and Nominating Committees, succeeding Dr. Magda Marquet, thereby enhancing the board's financial and strategic capabilities, which will improve the company's compliance and transparency in a complex regulatory environment.
- Industry Leadership Experience: Stover has served as CEO for multiple biotech firms, including Interpace Biosciences and Antares Pharma, where his successful integration efforts led to a sale for over $900 million, showcasing his exceptional ability to drive company growth.
- Future Development Vision: Stover expressed enthusiasm for helping TransCode achieve its mission of a cancer-free future, indicating the company's long-term commitment and strategic vision in cancer treatment, which may attract increased investor interest in its R&D potential.
See More
